您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Fenofibrate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Fenofibrate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Fenofibrate图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
200mg电议
5g电议
10g电议

产品介绍
Fenofibrate 是一种选择性 PPARα 激动剂,EC50 为 30 μM。

Cell lines

MCF-7 and Panc-1 cells

Preparation method

The solubility of this compound in DMSO is > 12.8 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months.

Reacting condition

24, 48 and 72 hrs

Applications

At 24th, 48th and 72th hrs, the IC50 values of Fenofibrate were 96.6, 46.5 and 9.2 μg/mL on Panc-1 cells, and 93.5, 55.9 and 8 μg/mL on MCF-7 cells, respectively. Compared with the untreated solvent control, MCF-7 and Panc-1 cells treated with 1/2 IC50, IC50 and 2 IC50 of Fenofibrate for 24 hrs exhibited a significant increase in the relative activity of caspase 3/7.

Animal models

Mice bearing Ehrlich ascites carcinoma (EAC)

Dosage form

200 mg/kg/day; p.o.; for 18 days

Applications

In an EAC mouse model, Fenofibrate significantly reduced tumor weight and volume, without affecting the relative heart weight. However, Fenofibrate treatment significantly decreased the body weight and increased the relative liver weight. In addition, a marked decrease in the carcinoembryonic antigen (CEA) level was also observed in the Fenofibrate treatment group.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

产品描述

Fenofibrate is a PPARα agonist with an EC50 of 30 μM.

Fenofibrate is a relatively potent inhibitor of CYP2B6 (IC50=0.7±0.2 μM) and CYP2C19 (IC50=0.2±0.1 μM). Fenofibrate is also a moderate inhibitor of CYP2C8 (IC50=4.8±1.7 μM) and CYP2C9 (IC50=9.7 μM)[1]. Fenofibrate binds to and inhibits cytochrome P450 epoxygenase (CYP)2C with higher affinity than to PPARα. Fenofibrate is a well-known PPARα agonist, but an in vitro assessment of 209 frequently prescribed drugs and related xenobiotics suggests that Fenofibrate is also a potent inhibitor of cytochrome P450 epoxygenase (CYP)2C. The affinity of Fenofibrate to CYP2C is >10 times higher (EC50=2.39±0.4 μM) than to PPARα (EC50=30 μM). Fenofibrate at a low dose inhibits CYP2C8 activity without PPARα activation[2].

Daily intake of Fenofibrate at this low dose (10 μg/g/day) inhibits retinal and choroidal neovascularization induced by CYP2C8 overexpression by 29% (P=0.021) and 36% (P=1.2×10–9) respectively[2].

References:
[1]. Schelleman H, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78(3):639-48.
[2]. Gong Y, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Sep 30. pii: S2352-3964(16)30448-0.